Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?

Abbott Laboratories (ABT) has significantly outperformed the broader Medical sector year-to-date, posting a 6.5% gain while the sector averaged a 5.7% decline. With a Zacks Rank #2 (Buy) and stable full-year earnings estimates, ABT also exceeded its specific Medical - Products industry's 3% YTD return, positioning it as a strong relative performer within the Medical group.

Analysis

Abbott Laboratories (ABT) is demonstrating significant relative strength, with its stock appreciating 6.5% year-to-date, in stark contrast to the broader Medical sector's average decline of 5.7%. This outperformance extends to its specific peer group, the Medical - Products industry, which has gained only 3% over the same period. The company's positive momentum is supported by a Zacks Rank of #2 (Buy), indicating a favorable short-term outlook. Despite the Zacks Consensus Estimate for ABT's full-year earnings remaining unchanged over the past quarter, the rating system interprets this stability as a positive signal for the earnings outlook. The context of the broader sector rankings makes Abbott's performance more notable; the Medical sector holds a middling rank of #8 out of 16, while Abbott's specific industry is ranked a relatively low #169, suggesting the company's gains are driven by firm-specific factors rather than a strong industry tailwind. For comparison, Astellas Pharma (ALPMY), another outperformer with a #2 (Buy) rank, has seen a substantial 13.5% increase in its current-year EPS estimate, though its stock gain of 0.7% YTD lags Abbott's.

Key Decisions for Investors

• Given Abbott's significant outperformance against both a declining sector and its direct industry peers, investors may consider it a resilient holding within the medical space.
• Monitor upcoming earnings reports and analyst estimate revisions for Abbott closely, as its current 'Buy' rating is predicated on a positive outlook despite a recent lack of upward revisions to its full-year consensus estimate.
• For diversification within the medical field, Astellas Pharma could be a stock to watch, as it shows stronger fundamental momentum with a 13.5% upward revision in its EPS estimate.